Tennessee Oncology, Pllc

Clinical research site in Nashville, Tennessee · 397 WALLACE RD, NASHVILLE, TN 37211-8025 · (615) 333-2481 · Website

Part of Tennessee Oncology

As of July 2026, 68 paid clinical trials are recruiting at Tennessee Oncology, Pllc in Nashville, Tennessee. Active studies at this site cover conditions such as Breast Cancer, Carcinoma, Non-Small-Cell Lung and Chronic Lymphocytic Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Tennessee Oncology, Pllc (68)

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

62 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for Breast Neoplasms

34 locations incl. Daphne

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07060807·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

86 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for Acute Myeloid Leukemia (AML)

42 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT07007312·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for Non-Small Cell Lung Cancer

26 locations incl. Irvine

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07100080·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for Chronic Lymphocytic Leukemia

35 locations incl. Laguna Hills

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06943872·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

41 locations incl. Tucson

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for Mantle Cell Lymphoma

41 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06742996·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

48 locations incl. Birmingham

Sponsor: Celgene

Sex: Male·Age: 18+

Code: NCT06764485·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

for Metastatic Colorectal Cancer

14 locations incl. Chandler

Sponsor: Amgen

Sex: All·Age: 18+

Code: NCT06252649·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

38 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for Advanced Melanoma

33 locations incl. Tucson

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT06112314·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

for Myelodysplastic Syndrome

24 locations incl. Gilbert

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07422480·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study of TAK-505 in Adults With Solid Tumors

for Malignant Solid Tumors

15 locations incl. Orange

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07436728·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

for Hepatocellular Carcinoma (HCC)

11 locations incl. Duarte

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07291076·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

for Metastatic Breast Cancer

6 locations incl. Saint Paul

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT03424005·Phase 1, Phase 2·Recruiting·Listed Feb 2018

Apply to this trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for Metastatic Hormone-sensitive Prostate Cancer

21 locations incl. La Jolla

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18+

Code: NCT06991556·Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for Multiple Myeloma

15 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06121843·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

15 locations incl. Watertown

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06465329·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

for Prostatic Neoplasms

11 locations incl. Aurora

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT06095089·Phase 1·Recruiting·Listed Oct 2023

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

for Somatostatin Receptor Positive (SSTR+)

18 locations incl. Scottsdale

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 12 - 100

Code: NCT06784752·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Study of INCB123667 in Subjects With Advanced Solid Tumors

for Solid Tumors

11 locations incl. Duarte

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05238922·Phase 1·Recruiting·Listed Feb 2022

Apply to this trial

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

for NSCLC Stage IV

19 locations incl. Springdale

Sponsor: ImmunityBio, Inc.

Sex: All·Age: 18 - 90

Code: NCT06745908·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Showing the 40 most relevant of 68 recruiting trials at this site. Browse all with filters →

More research sites in Nashville

Vanderbilt University Medical Center (369 trials)
SCRI Oncology Partners (127 trials)
Vanderbilt University/Ingram Cancer Center (86 trials)
Sarah Cannon Research Institute (62 trials)
Vanderbilt University (55 trials)
Tennessee Oncology (48 trials)
Vanderbilt-Ingram Cancer Center (39 trials)
The Children's Hospital at TriStar Centennial (28 trials)
Monroe Carell Jr. Children's Hospital at Vanderbilt (13 trials)
TriStar Centennial Medical Center (12 trials)

Explore more

Paid clinical trials in Nashville, TN · Tennessee clinical trials